0000000000795360
AUTHOR
Wojciech Barg
Metabolomics of chronic obstructive pulmonary disease and obstructive sleep apnea syndrome : response to Maniscalco and Motta
We appreciate Maniscalco and Motta’s comments on our recently published article “Fusion of the 1H NMR data of serum, urine and exhaled breath condensate in order to discriminate chronic obstructive pulmonary disease and obstructive sleep apnea syndrome” (Zabek et al. 2015) and we are grateful for the opportunity to clarify a number of points from our work. We are glad that the authors appreciated our data analysis and interpretation. Fusion of metabolomic data is an outstanding tool for a comprehensive description of patient’s phenotype that combines metabolic profiles acquired in different domains. Such an integrative approach is highly valued in the so-called ‘breathomics’ (Smolinska et a…
Fusion of the 1H NMR data of serum, urine and exhaled breath condensate in order to discriminate chronic obstructive pulmonary disease and obstructive sleep apnea syndrome
Chronic obstructive pulmonary disease, COPD, affects the condition of the entire human organism and causes multiple comorbidities. Pathological lung changes lead to quantitative changes in the composition of the metabolites in different body fluids. The obstructive sleep apnea syndrome, OSAS, occurs in conjunction with chronic obstructive pulmonary disease in about 10–20 % of individuals who have COPD. Both conditions share the same comorbidities and this makes differentiating them difficult. The aim of this study was to investigate whether it is possible to diagnose a patient with either COPD or the OSA syndrome using a set of selected metabolites and to determine whether the metabolites t…
Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) and lung cancer are widespread lung diseases. Cigarette smoking is a high risk factor for both the diseases. COPD may increase the risk of developing lung cancer. Thus, it is crucial to be able to distinguish between these two pathological states, especially considering the early stages of lung cancer. Novel diagnostic and monitoring tools are required to properly determine lung cancer progression because this information directly impacts the type of the treatment prescribed. In this study, serum samples collected from 22 COPD and 77 lung cancer (TNM stages I, II, III, and IV) patients were analyzed. Then, a collection of NMR metabolic fingerprin…